Immunomedics (IMMU -2.2%) finishes the day lower, despite reporting favorable results from the...

|By:, SA News Editor

Immunomedics (IMMU -2.2%) finishes the day lower, despite reporting favorable results from the study of its proprietary humanized antibody, clivatuzumab tetraxetan, as a treatment for patients with advanced, inoperable, pancreatic cancer.